Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis.
LC-MS/MS
docosahexaenoic acid
gas chromatography
hyperlipoproteinaemia
lipid apheresis
lipid mediators
lipidomics
n-3 PUFA
n-6 PUFA.
omega-3 polyunsaturated fatty acids, eicosapentaenoic acid
oxylipins
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
09 Feb 2019
09 Feb 2019
Historique:
received:
26
10
2018
revised:
02
02
2019
accepted:
05
02
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
26
4
2019
Statut:
epublish
Résumé
Lipoprotein apheresis reliably reduces low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). Besides lowering lipoproteins and triglycerides, apheresis also decreases levels of essential omega-6 and omega-3 polyunsaturated fatty acids (
Identifiants
pubmed: 30744123
pii: nu11020363
doi: 10.3390/nu11020363
pmc: PMC6412478
pii:
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Fatty Acids, Omega-6
0
Lipoproteins, LDL
0
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Mol Neurosci. 2001 Apr-Jun;16(2-3):159-65; discussion 215-21
pubmed: 11478370
Physiol Rev. 2002 Jan;82(1):131-85
pubmed: 11773611
Diabetologia. 2002 Jan;45(1):125-33
pubmed: 11845232
Biomed Pharmacother. 2002 Jul;56(5):215-22
pubmed: 12199620
Circulation. 2003 Jun 3;107(21):2646-52
pubmed: 12782616
Prog Lipid Res. 2004 Jan;43(1):55-90
pubmed: 14636671
Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):163-77
pubmed: 16125378
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2301-7
pubmed: 16166569
Lancet. 2007 Mar 31;369(9567):1090-8
pubmed: 17398308
Exp Biol Med (Maywood). 2008 Jun;233(6):674-88
pubmed: 18408140
J Lipid Res. 2009 Jun;50(6):1015-38
pubmed: 19244215
JAMA. 2009 Jun 10;301(22):2331-9
pubmed: 19509380
Atherosclerosis. 2010 Jul;211(1):15-23
pubmed: 20106478
Atheroscler Suppl. 2009 Dec 29;10(5):79-84
pubmed: 20129381
Arterioscler Thromb Vasc Biol. 2010 May;30(5):1058-65
pubmed: 20203302
Cytokine. 2011 Aug;55(2):245-50
pubmed: 21561790
N Engl J Med. 2011 Jun 23;364(25):2439-50
pubmed: 21696310
Circulation. 2011 Nov 15;124(20):2202-7
pubmed: 21986285
FASEB J. 2012 Apr;26(4):1755-65
pubmed: 22253477
Prostaglandins Other Lipid Mediat. 2012 Mar;97(3-4):73-82
pubmed: 22326554
ScientificWorldJournal. 2012;2012:314283
pubmed: 22654591
Atheroscler Suppl. 2013 Jan;14(1):107-13
pubmed: 23357151
Atherosclerosis. 2013 Apr;227(2):442-8
pubmed: 23466098
Thromb Haemost. 2013 Jun;109(6):1099-107
pubmed: 23494053
Circulation. 2013 Dec 17;128(24):2567-76
pubmed: 24056686
Biomacromolecules. 2014 Jul 14;15(7):2648-55
pubmed: 24844344
J Lipid Res. 2014 Oct;55(10):2064-72
pubmed: 25121984
PLoS One. 2014 Nov 19;9(11):e113480
pubmed: 25409514
Prostaglandins Leukot Essent Fatty Acids. 2014 Dec;91(6):235-41
pubmed: 25458899
Anal Bioanal Chem. 2015 Feb;407(5):1403-14
pubmed: 25542569
Clin Res Cardiol Suppl. 2015 Apr;10:8-13
pubmed: 25672934
Clin Res Cardiol Suppl. 2015 Apr;10:2-7
pubmed: 25686595
Atherosclerosis. 2015 Apr;239(2):557-65
pubmed: 25733327
Atherosclerosis. 2016 Jun;249:30-5
pubmed: 27062407
Med Devices (Auckl). 2016 Oct 13;9:349-360
pubmed: 27785114
Pharmacol Ther. 2018 Mar;183:177-204
pubmed: 29080699
Atheroscler Suppl. 2017 Nov;30:193-199
pubmed: 29096838
Int J Mol Sci. 2018 Jan 08;19(1):null
pubmed: 29316682
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
J Lipid Res. 1964 Jul;5(3):307-13
pubmed: 5873366